| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
41,560,000 |
| Market
Cap: |
257.67(M) |
| Last
Volume: |
5,200 |
Avg
Vol: |
5,186 |
| 52
Week Range: |
$3.61 - $10.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Axogen is focused on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Co.'s platform for peripheral nerve repair features a portfolio of products, including Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; and Axoguard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Co. also provides Axotouch Two-Point Discriminator, which is used to measure the innervation density of any surface area of the skin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
30,000 |
30,000 |
| Total Buy Value |
$0 |
$0 |
$188,940 |
$188,940 |
| Total People Bought |
0 |
0 |
3 |
3 |
| Total Buy Transactions |
0 |
0 |
3 |
3 |
| Total Shares Sold |
118,082 |
130,582 |
180,030 |
368,410 |
| Total Sell Value |
$980,899 |
$1,074,708 |
$1,509,387 |
$3,484,755 |
| Total People Sold |
5 |
6 |
6 |
6 |
| Total Sell Transactions |
6 |
7 |
9 |
21 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hansen David K |
VP Finance & Treasurer |
• – – |
2019-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,930 |
46,161 |
|
- |
|
| Friedman Mark Louis |
VP,Regulatory & Quality |
• – – |
2019-02-15 |
4 |
D |
$17.57 |
$10,068 |
D/D |
(573) |
69,512 |
|
- |
|
| Friedman Mark Louis |
VP,Regulatory & Quality |
• – – |
2019-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,930 |
70,085 |
|
- |
|
| Mariani Peter J |
Chief Financial Officer |
• – – |
2019-02-15 |
4 |
D |
$17.57 |
$41,377 |
D/D |
(2,355) |
9,682 |
|
- |
|
| Mariani Peter J |
Chief Financial Officer |
• – – |
2019-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
7,654 |
12,037 |
|
- |
|
| Zaderej Karen L. |
CEO |
• • – |
2019-02-15 |
4 |
A |
$17.57 |
$281,384 |
D/D |
16,015 |
492,224 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2019-02-15 |
4 |
D |
$17.57 |
$10,068 |
D/D |
(573) |
38,974 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2019-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,930 |
39,547 |
|
- |
|
| Devinney Erick Wayne |
VP, Clinical&Translational Sc |
• – – |
2019-02-15 |
4 |
D |
$17.57 |
$26,320 |
D/D |
(1,498) |
41,971 |
|
- |
|
| Devinney Erick Wayne |
VP, Clinical&Translational Sc |
• – – |
2019-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,079 |
43,469 |
|
- |
|
| Freitag Gregory Gene |
General Counsel |
• • – |
2018-11-30 |
4 |
AS |
$33.00 |
$1,485,000 |
D/D |
(45,000) |
95,865 |
|
- |
|
| Zaderej Karen L. |
CEO |
• • – |
2018-11-19 |
4 |
OE |
$2.74 |
$82,200 |
D/D |
30,000 |
476,209 |
|
- |
|
| Zaderej Karen L. |
CEO |
• • – |
2018-11-19 |
4 |
D |
$28.37 |
$191,810 |
D/D |
(6,761) |
446,209 |
|
- |
|
| Zaderej Karen L. |
CEO |
• • – |
2018-11-19 |
4 |
OE |
$2.74 |
$191,800 |
D/D |
70,000 |
452,970 |
|
- |
|
| Gold Mark Stephen |
Director |
– • – |
2018-10-02 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
344,761 |
|
- |
|
| Grooms Jamie Mark |
Director |
– • – |
2018-09-20 |
4 |
OE |
$0.27 |
$33,133 |
D/D |
12,494 |
18,693 |
|
- |
|
| Wendell Amy Mcbride |
Director |
– • – |
2018-08-14 |
4 |
B |
$36.89 |
$184,450 |
D/D |
5,000 |
18,333 |
2.39 |
- |
|
| Gold Mark Stephen |
Director |
– • – |
2018-08-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
30,487 |
344,761 |
|
- |
|
| Mccarrey Shawn F |
SVP Sales |
• – – |
2018-08-07 |
4 |
D |
$39.30 |
$201,845 |
D/D |
(5,136) |
82,921 |
|
- |
|
| Mccarrey Shawn F |
SVP Sales |
• – – |
2018-08-07 |
4 |
OE |
$3.67 |
$201,850 |
D/D |
55,000 |
88,057 |
|
- |
|
| Zaderej Karen L. |
CEO |
• • – |
2018-08-07 |
4 |
D |
$39.30 |
$395,358 |
D/D |
(10,060) |
407,970 |
|
- |
|
| Zaderej Karen L. |
CEO |
• • – |
2018-08-02 |
4 |
OE |
$2.74 |
$479,500 |
D/D |
175,000 |
418,030 |
|
- |
|
| Rudelius Robert James |
Director |
– • – |
2018-06-08 |
4 |
D |
$48.40 |
$33,009 |
D/D |
(682) |
34,591 |
|
- |
|
| Rudelius Robert James |
Director |
– • – |
2018-06-08 |
4 |
OE |
$2.75 |
$33,000 |
D/D |
12,000 |
35,273 |
|
- |
|
| Gold Mark Stephen |
Director |
– • – |
2018-06-01 |
4 |
OE |
$14.85 |
$222,750 |
D/D |
15,000 |
375,248 |
|
- |
|
529 Records found
|
|
Page 15 of 22 |
|
|
0.11 (1.81%) 
